Long-acting β-agonist prescribing in people with asthma in primary care

Daniel R. Morales, Cathy Jackson, Shona Fielding, Bruce Guthrie

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Long-acting β2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.
Original languageEnglish
Pages (from-to)192-194
Number of pages3
JournalThorax
Volume68
Issue number2
Early online date1 Sep 2012
DOIs
Publication statusPublished - Feb 2013

Fingerprint Dive into the research topics of 'Long-acting β-agonist prescribing in people with asthma in primary care'. Together they form a unique fingerprint.

Cite this